pharmaphorum December 7, 2023
Phil Taylor

Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.

The deal was first announced in May and had been due to be completed by the end of the year, with Medtronic offering $738 million for the business, saying it would combine EOFlow’s tubeless, wearable, and fully disposable EOPatch with its continuous glucose monitor (CGM) devices and artificial intelligence algorithms to create a “seamless” system to help patients manage their illness.

Now, it said in a regulatory filing that it has “exercised its right to terminate the agreements” with the South Korean company and does not believe any...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Medical Devices, Mergers & Acquisitions / JV, Technology, Trends, Wearables
10 Ways To Drive Change In Healthcare
Regaining Speech: Implementing Neuroprosthetic Solutions
Baxter considers selling kidney care unit to private equity
Healthcare Spending 2000-2022: Key Trends, Five Important Questions
FDA approves combo test for flu, COVID-19; alerts providers to medical device risks

Share This Article